⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

June 29, 2017JAMA OncologyOpen Access

Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression

Georgina V. Long Jeffrey S. Weber James Larkin Victoria Atkinson Jean‐Jacques Grob Dirk Schadendorf Reinhard Dummer Caroline Robert Iván Márquez‐Rodas Catriona M. McNeil Henrik Schmidt Karen Briscoe Jean‐François Baurain F. Stephen Hodi Jedd D. Wolchok

View Full Paper

Ask AI

Bookmark

Share

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Abstract

clinicaltrials.gov Identifiers: NCT01721772 (CheckMate 066) and NCT01844505 (CheckMate 067).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Long et al. (2017) studied this question.

synapsesocial.com/papers/69d92573e0d31bb747835ee3 https://doi.org/10.1001/jamaoncol.2017.1588

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 related papers. Consider them for comparative context:

1Rilvegostomig Plus Trastuzumab-Deruxtecan for Early-Stage Breast CancerJAMA Oncology · Thu,
2“Low-Risk” Ovarian Lesions—The Case for Early Follow-UpJAMA Oncology · Thu,
3Long-Term Outcomes of De-Escalated 30-Gy Elective Irradiation in HPV-Associated Oropharyngeal CancerJAMA Oncology · Thu,
4Neoadjuvant Stereotactic Ablative Radiotherapy Before Inferior Vena Cava Thrombectomy for Renal Cell CarcinomaJAMA Oncology · Thu,
5Nivolumab-Ipilimumab for Localized Microsatellite Instability–High Gastric/Gastroesophageal Junction AdenocarcinomaJAMA Oncology · Thu,

More from JAMA Oncology

Beyond Tumor Size, Toward Meaningful Patient Outcomes—Resisting RECISTThu,
Disitamab Vedotin Plus Tislelizumab in Transurethrally Unresectable, ERBB2 -Positive, Non–Muscle-Invasive Bladder CancerThu,
Rethinking Treatment Intensification in Poorly Chemosensitive Ovarian CancerThu,
Immune Checkpoint Inhibitor–Based Downstaging Therapy for Hepatocellular CarcinomaThu,
Rethinking Value in Cancer Care in the USThu,